- Home
- HCM
HCM
HUTCHMED (China) Limited
as 11-15-2024 4:00pm EST
| Founded: | 2000 | Country: | Hong Kong |
| Employees: | N/A | City: | N/A |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $20.55 | AVG Volume (30 days): | 80.2K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.93 - $21.92 | Next Earning Date: | 07-31-2024 |
| Revenue: | $610,806,000 | Revenue Growth: | -19.34% |
| Revenue Growth (this year): | -17.22% | Revenue Growth (next year): | 21.06% |
Latest HUTCHMED (China) Limited News
HCM Breaking Stock News: Dive into HCM Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 days ago
HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress
GlobeNewswire
18 days ago
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
GlobeNewswire
a month ago
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
GuruFocus.com
a month ago
HUTCHMED (China) Ltd (HCM) (Q2 2024) Earnings Call Highlights: Strong US Sales Propel Growth ...
Simply Wall St.
2 months ago
HUTCHMED (China) (LON:HCM) shareholders are up 17% this past week, but still in the red over the last three years
GlobeNewswire
2 months ago
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
GlobeNewswire
2 months ago
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
GlobeNewswire
2 months ago
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024
Compare HCM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HCM HUTCHMED (China) Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.